Skip to main content
. 2019 Feb 2;1(2):112–117. doi: 10.1253/circrep.CR-18-0006

Table.

Entire Cohort: Baseline Information

Variable n=1,218
Age (years) 79±13
Male 667 (54.8)
BMI (kg/m2) 22±4
Living circumstances
 Alone 264 (21.7)
 With family member 892 (73.2)
 With only spouse 390 (32.0)
 Nursing home 62 (5.1)
History of symptomatic HF
 First time 814 (66.8)
 Second time 208 (17.1)
 ≥Three times 196 (16.1)
Underlying heart disease
 Ischemic 319 (26.2)
 Valvular 430 (35.3)
 Hypertensive 369 (30.3)
 Others 424 (34.8)
HF severity at admission
 NYHA I 19 (1.6)
 NYHA II 178 (14.6)
 NYHA III 652 (53.5)
 NYHA IV 369 (30.3)
Comorbidity
 Hypertension 779 (64.0)
 Diabetes mellitus 365 (30.0)
 Dyslipidemia 262 (21.5)
 Atrial fibrillation 533 (43.8)
 CKD 499 (41.0)
 Obesity (BMI ≥28) 69 (5.7)
 Smoking 314 (25.8)
 COPD 104 (8.5)
Biomarker (pg/mL)
 BNP (n=1,062) 602 (345–1,129)
 NT-proBNP (n=134) 4,431 (2,028–11,313)
EF (%) (n=1,114)§ 45.9±16.3
HFpEF (EF ≥50%)§
 ≤64 years (n=141) 32 (22.7)
 65–84 years (n=540) 227 (42.0)
 ≥85 years (n=433) 230 (53.1)

Data given as n (%), mean±SD or median (IQR). Some patients had 2 or more underlying heart diseases. Serum BNP or NT-proBNP measured at the time of admission. §Echocardiogram at the time of admission. BMI, body mass index; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; EF, ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.